Pfizer’s HYMPAVZI Gains FDA Nod for Hemophilia A and B Without Inhibitors
Pfizer Inc. announced the FDA approval of HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing the frequency of bleeding episodes. This approval covers both adult and p ...